At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC
In Brief
A Phase 3 clinical trial evaluating Amrubicin Hydrochloride and Etoposide-Cisplatin combined chemotherapy for Lung Cancer. Completed, enrolled 300 participants across 15 sites.
Detailed Summary
This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.
Study Details
Timeline
Interventions
Amrubicin Hydrochloride combined with cisplatin
combined chemotherapy